Straten Pt - Search Results

1

Identification of an HLA-A3-restricted cytotoxic T lymphocyte (CTL) epitope from ML-IAP.

Andersen MH, Becker JC, Straten Pt. Andersen MH, et al. Among authors: straten pt. J Invest Dermatol. 2004 May;122(5):1336-7. doi: 10.1111/j.0022-202X.2004.22508.x. J Invest Dermatol. 2004. PMID: 15140242 No abstract available.

2

Accumulation of identical T cells in melanoma and vitiligo-like leukoderma.

Becker JC, Guldberg P, Zeuthen J, Bröcker EB, Straten PT. Becker JC, et al. Among authors: straten pt. J Invest Dermatol. 1999 Dec;113(6):1033-8. doi: 10.1046/j.1523-1747.1999.00805.x. J Invest Dermatol. 1999. PMID: 10594748

3

A promiscuous survivin-derived T-cell epitope restricted to the HLA-A3 super-type alleles.

Junker N, Munir S, Kvistborg P, Straten Pt, Svane IM, Andersen MH. Junker N, et al. Among authors: straten pt. J Invest Dermatol. 2012 Aug;132(8):2115-8. doi: 10.1038/jid.2012.109. Epub 2012 Apr 19. J Invest Dermatol. 2012. PMID: 22513782 No abstract available.

4

A TGF betaRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8+ T cells.

Saeterdal I, Gjertsen MK, Straten P, Eriksen JA, Gaudernack G. Saeterdal I, et al. Cancer Immunol Immunother. 2001 Nov;50(9):469-76. doi: 10.1007/s002620100222. Cancer Immunol Immunother. 2001. PMID: 11761441

5

HLA-A2-restricted survivin-derived T-cell responses.

Straten PT, Andersen MH. Straten PT, et al. Vaccine. 2011 Dec 6;29(52):9582. doi: 10.1016/j.vaccine.2011.04.085. Epub 2011 May 11. Vaccine. 2011. PMID: 21569816 No abstract available.

6

Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients.

Andersen MH, Pedersen LO, Becker JC, Straten PT. Andersen MH, et al. Among authors: straten pt. Cancer Res. 2001 Feb 1;61(3):869-72. Cancer Res. 2001. PMID: 11221872

7

Identification and characterization of survivin-derived H-2Kb-restricted CTL epitopes.

Hofmann UB, Voigt H, Andersen MH, Straten PT, Becker JC, Eggert AO. Hofmann UB, et al. Among authors: straten pt. Eur J Immunol. 2009 May;39(5):1419-24. doi: 10.1002/eji.200839098. Eur J Immunol. 2009. PMID: 19337999

8

HLA-B35-restricted immune responses against survivin in cancer patients.

Reker S, Becker JC, Svane IM, Ralfkiaer E, Straten PT, Andersen MH. Reker S, et al. Among authors: straten pt. Int J Cancer. 2004 Mar 1;108(6):937-41. doi: 10.1002/ijc.11634. Int J Cancer. 2004. PMID: 14712500

9

Expression of CD94/NKG2 subtypes on tumor-infiltrating lymphocytes in primary and metastatic melanoma.

Vetter CS, Straten PT, Terheyden P, Zeuthen J, Bröcker EB, Becker JC. Vetter CS, et al. Among authors: straten pt. J Invest Dermatol. 2000 May;114(5):941-7. doi: 10.1046/j.1523-1747.2000.00958.x. J Invest Dermatol. 2000. PMID: 10771475

10

Possible benefits of the targeting of indoleamine 2,3-dioxygenase (IDO) in hepatitis B vaccination.

Straten PT, Andersen MH. Straten PT, et al. Vaccine. 2011 May 12;29(21):3728. doi: 10.1016/j.vaccine.2011.03.007. Epub 2011 Mar 21. Vaccine. 2011. PMID: 21420415 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results